Zoltan Greff
Overview
Explore the profile of Zoltan Greff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
774
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bragelmann J, Dammert M, Dietlein F, Heuckmann J, Choidas A, Bohm S, et al.
Cell Rep
. 2017 Sep;
20(12):2833-2845.
PMID: 28930680
Kinase inhibitors represent the backbone of targeted cancer therapy, yet only a limited number of oncogenic drivers are directly druggable. By interrogating the activity of 1,505 kinase inhibitors, we found...
2.
Simon-Szabo L, Kokas M, Greff Z, Boros S, Banhegyi P, Zsakai L, et al.
Bioorg Med Chem Lett
. 2015 Dec;
26(2):424-428.
PMID: 26704265
Activation of various interacting stress kinases, particularly the c-Jun N-terminal kinases (JNK), and a concomitant phosphorylation of insulin receptor substrate 1 (IRS-1) at serine 307 play a central role both...
3.
Varga A, Gyulavari P, Greff Z, Futosi K, Nemeth T, Simon-Szabo L, et al.
PLoS One
. 2015 Dec;
10(12):e0144792.
PMID: 26672602
No abstract available.
4.
Varga A, Gyulavari P, Greff Z, Futosi K, Nemeth T, Simon-Szabo L, et al.
PLoS One
. 2015 Apr;
10(4):e0124234.
PMID: 25874616
Emerging evidence suggests that the vascular endothelial growth factor receptor 2 (VEGFR2) and protein kinase D1 (PKD1) signaling axis plays a critical role in normal and pathological angiogenesis and inflammation...
5.
Kekesi L, Sipos A, Nemeth G, Dancso A, Illyes E, Boros S, et al.
Acta Pharm Hung
. 2014 Dec;
84(3):91-104.
PMID: 25470976
The EGFR inhibitor erlotinib possesses high anti-tumor effect but despite the good clinical responses in most of the cases recrudescence occures. This can be attributed to a secondary, acquired mutation...
6.
Rybniker J, Chen J, Sala C, Hartkoorn R, Vocat A, Benjak A, et al.
Cell Host Microbe
. 2014 Oct;
16(4):538-48.
PMID: 25299337
Mycobacterium tuberculosis (Mtb) requires protein secretion systems like ESX-1 for intracellular survival and virulence. The major virulence determinant and ESX-1 substrate, EsxA, arrests phagosome maturation and lyses cell membranes, resulting...
7.
Szokol B, Gyulavari P, Kurko I, Baska F, Szantai-Kis C, Greff Z, et al.
ACS Med Chem Lett
. 2014 Jun;
5(4):298-303.
PMID: 24900830
Activating mutations in the epidermal growth factor receptor (EGFR) have been identified in a subset of non-small cell lung cancer (NSCLC), which is one of the leading cancer types worldwide....
8.
Nemeth G, Greff Z, Sipos A, Varga Z, Szekely R, Sebestyen M, et al.
J Med Chem
. 2014 Apr;
57(10):3939-65.
PMID: 24742150
Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The...
9.
Szokol B, Gyulavari P, Baska F, Ibolya K, Greff Z, Szantai K, et al.
Acta Pharm Hung
. 2014 Mar;
83(4):121-33.
PMID: 24575658
The epidermal growth factor receptor (EGFR) family has been well-known for more than ten years as the target of non-small lung carcinoma (NSCLC) which is one of the leading cause...
10.
Baska F, Szekely E, Szantai-Kis C, Banhegyi P, Hegymegi-Barakonyi B, Nemeth G, et al.
Acta Pharm Hung
. 2013 Dec;
83(3):88-95.
PMID: 24369587
Tuberculosis is considered to be one of the major health problem not only in the less developed countries but in the economically developed countries as well. Roughly one third of...